ACM
ABUS icon

ADAR1 Capital Management’s Arbutus Biopharma ABUS Stock Holding History

ADAR1 Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.09M Sell
1,268,147
-1,865,028
-60% -$8.19M 0.28% 83
2026
Q1 		$14.1M Sell
3,133,175
-2,281,934
-42% -$9.98M 0.83% 26
2025
Q4 		$26M Buy
5,415,109
+2,511,883
+87% +$11.3M 1.91% 10
2025
Q3 		$13.2M Buy
2,903,226
+77,453
+3% +$284K 1.24% 15
2025
Q2 		$8.73M Buy
2,825,773
+946,659
+50% +$3.14M 1.34% 16
2025
Q1 		$6.56M Buy
1,879,114
+324,312
+21% +$1.08M 1.22% 20
2024
Q4 		$5.08M Sell
1,554,802
-534,519
-26% -$1.97M 1.02% 24
2024
Q3 		$8.04M Sell
2,089,321
-1,199,939
-36% -$4.6M 1.31% 15
2024
Q2 		$10.2M Buy
3,289,260
+1,215,077
+59% +$3.65M 1.92% 10
2024
Q1 		$5.35M Sell
2,074,183
-1,394,641
-40% -$3.61M 1.21% 13
2023
Q4 		$8.67M Buy
+3,468,824
New +$6.79M 3.1% 5

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

ADAR1 Capital Management's ABUS Position: Q2 2026 in Review

ADAR1 Capital Management reduced its Arbutus Biopharma (ABUS) stake by 60% in Q2 2026, selling an estimated $8.19M and leaving 1,268,147 shares worth $6.09M. The position accounts for 0.28% of the portfolio, ranked #83.

ADAR1 Capital Management first reported a position in ABUS in Q4 2023 and has held it in 11 quarters since. The position peaked at $26M in Q4 2025. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • ADAR1 Capital Management held 1,268,147 shares of Arbutus Biopharma worth $6.09M as of Q2 2026.
  • ADAR1 Capital Management sold 1,865,028 Arbutus Biopharma shares in Q2 2026, an estimated $8.19M.
  • Arbutus Biopharma made up 0.28% of ADAR1 Capital Management's portfolio in Q2 2026, its #83 holding.
  • ADAR1 Capital Management first reported a position in Arbutus Biopharma in Q4 2023 and has held it in 11 quarters since.
  • ADAR1 Capital Management's Arbutus Biopharma position peaked at $26M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.